How does sex hormone-binding globulin work?

Sex hormone-binding globulin (SHBG) is the circulating transport glycoprotein that binds testosterone, dihydrotestosterone and estradiol with high affinity, thereby regulating the fraction of those steroids that is free and biologically available to tissue. It is also referred to in the literature as sex steroid-binding globulin (SSBG) and, historically, as testosterone-estradiol-binding globulin (TeBG). The evidence block available for this page does not supply a sequence, a molecular formula or a molecular weight for the protein, so none is stated here. The class designation that the indexed material supports is that of a hepatic-derived plasma binding protein whose circulating concentration is a readout of the endocrine and metabolic state of the individual.

The pathway the indexed work centres on is the insulin–androgen axis in polycystic ovary syndrome (PCOS). In the framing used by the registered studies below, hyperinsulinaemia acts on the liver to reduce hepatic SHBG synthesis, which raises the free androgen fraction and aggravates hyperandrogenism and reproductive dysfunction [1].

Research Studies

SHBG and hepatic synthesis in the insulin-resistant PCOS model

The mechanistic account given in the indexed trial record is that insulin resistance is central to the pathophysiology of PCOS, and that compensatory hyperinsulinaemia has two convergent effects: it enhances ovarian androgen production and it reduces hepatic SHBG synthesis [1]. The reduction in SHBG is described as a hepatic effect, which places the liver — rather than the gonad — as the tissue where the binding-protein arm of the mechanism is set. The consequence stated in the record is that a lower SHBG concentration aggravates hyperandrogenism and the associated reproductive abnormalities [1]. This is a mechanistic description embedded in a registered interventional protocol; it is not reported here as an outcome that has been measured and published.

Vildagliptin and the insulin–SHBG relationship in PCOS

Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. The indexed record states that DPP-4 inhibition enhances endogenous incretin activity and may improve insulin sensitivity and glucose homeostasis, and that emerging evidence suggests DPP-4 inhibition may also influence body weight, androgen excess and inflammation [1]. Because the same record links hyperinsulinaemia to reduced hepatic SHBG synthesis, the implied mechanistic chain is that an intervention acting on insulin sensitivity could act upstream of SHBG. The record does not report SHBG as a measured endpoint, and no effect size is given. The comparison under study is vildagliptin versus metformin in patients with PCOS [1].

SHBG, adiposity and hepatic steatosis in adolescent girls

A separate registered observational study addresses whether PCOS contributes to hepatic steatosis in adolescent girls independently of adiposity [2]. The design is a single-centre, prospective, observational, cross-sectional mechanistic pilot study enrolling 150 girls aged 10–18 years into three groups of 50: girls with PCOS and obesity, age- and body-mass-index-matched girls with obesity but without PCOS, and healthy normal-weight girls [2]. Each participant undergoes a single evaluation comprising anthropometry, clinical and biochemical phenotyping, transient elastography with controlled attenuation parameter, two-dimensional shear wave elastography, and a single venous blood sample [2]. The three-group structure is what allows the adiposity-independent question to be posed at all: the obesity-without-PCOS arm separates the effect of excess adiposity from the effect of PCOS itself. SHBG is not named as an endpoint in the indexed excerpt; the biochemical phenotyping is described only at the level of a single venous sample.

Model comparison across the indexed studies

The two records differ in the population studied, the design, and the role assigned to SHBG. The table below sets out what each record states.

What the indexed evidence does not establish

Neither record reports a measured SHBG concentration, a change in SHBG, or an association between SHBG and any clinical outcome. The mechanistic statement that hyperinsulinaemia reduces hepatic SHBG synthesis appears as background framing within a registered protocol [1], not as a result. No animal-only or in vitro data are supplied by the evidence block for this page, and none is asserted. Where a claim is not supported by the indexed material, it has been left out.

Reading the mechanism from the available record

Taken together, the indexed material supports a description of SHBG as the hepatic output of an insulin-sensitive pathway: insulin resistance and the resulting hyperinsulinaemia are stated to lower hepatic SHBG synthesis, and a lower SHBG concentration is stated to aggravate hyperandrogenism [1]. The adolescent study supplies the population in which the adiposity-independent question about PCOS and liver fat is being asked, but does not itself report SHBG values [2]. Any statement beyond this — about direction of effect in a treated population, about magnitude, or about clinical consequence — is not available from the evidence provided.

If you are reading this for personal health reasons

The materials described on this page are supplied for laboratory research use only. We do not provide dosing information, medical guidance, or recommendations for personal use of any compound. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] Efficacy of Vildagliptin Versus Metformin in Patients With Polycystic Ovary Syndrome — ClinicalTrials.gov
• [2] Biomarker Panel for PCOS-Associated Liver Steatosis in Adolescent Girls (COMPASS-pedPCOS) — ClinicalTrials.gov